Role of transurethral resection of the prostate in population-based prostate cancer incidence rates

American Journal of Epidemiology

Volumn 150, Issue 8, 1999, Pages 848-860

  Merrill, Ray M ^a,b   Feuer, Eric J ^c   Warren, Joan L ^c   Schussler, Nicki ^d   Stephenson, Robert A ^b  

^a BRIGHAM YOUNG UNIVERSITY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

Medicare; Prostate specific antigen; Prostatectomy; Prostatic neoplasms; SEER Program

Indexed keywords

ARTICLE; CANCER INCIDENCE; CANCER RISK; DATA ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICARE; PROSTATE CANCER; TRANSURETHRAL RESECTION; UNITED STATES;

EID: 0033570081     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a010090     Document Type: Article

References (47)

1. Parker SL, Tong T, Bolden S. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Merrill RM, Brawley OW. Prostate cancer incidence and mortality rates among white and black men. Epidemiology 1997;8: 126-31.
3. Gilliland FD, Welsh DJ, Hoffman RM, et al. Rapid rise and subsequent decline in prostate cancer incidence rates for New Mexico, 1989-1993. Cancer Epidemiol Biomarkers Prev 1995;4:797-800.
4. Stephenson RA, Smart CR, Mineau GP, et al. The fall in incidence of prostate carcinoma. On the down side of prostate specific antigen induced peak in incidence-data from the Utah Cancer Registry. Cancer 1996;77:1342-8.
5. Stanford JL, Wicklund KG, Blumenstein BA. The changing epidemiology of prostate cancer in Seattle-Puget sound region, 1974-1993. (Abstract). J Urol 1995;153:504.
6. Merrill RM, Potosky A, Feuer E. Changing trends in U.S. prostate cancer incidence rates. J Natl Cancer Inst 1996;88: 1683-5.
7. Polednak AP. Trends in prostate carcinoma incidence in Connecticut (1988-1994) by age and race. Cancer 1997;79: 99-103.
8. Ries L, Kosary C. Prostate cancer incidence, 1973-1994: NCI releases new cancer statistics (Stat Bite). J Natl Cancer Inst 1997;89:609.
9. Andrews GS. Latent carcinoma of the prostate. J Clin Pathol 1949;2:197.
10. Edwards CN, Steinthorsson E, Nicholson D. An autopsy of latent prostatic cancer. Cancer 1953;6:531.
11. Hirst, AE Jr, Bergman RT. Carcinoma of the prostate in men 80 or more years old. Cancer 1954;7:136.
12. Whitmore WF Jr. Symposium of hormones and cancer therapy hormone therapy in prostatic cancer. Am J Med 1956;21:295.
13. Scott R Jr, Mutchnik DL, Laskowski TZ, et al. Carcinoma of the prostate in elderly men: incidence, growth characteristics and clinical significance. J Urol 1969;101:602-7.
14. Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of the prostate at autopsy in seven areas. Int J Cancer 1977;20:680-8.
15. Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990;143:742-6.
16. Catalona WJ, Smith DS, Ratliff TL, et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948-54.
17. Potosky AL, Miller BA, Albertsen PC, et al. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548-52.
18. Potosky AL, Kessler L, Gridley G, et al. Rise in prostatic cancer incidence associated with increased use of transurethral resection. J Natl Cancer Inst 1990;82:1624-8.
19. Levy IG, Gibbons L, Collins JP, et al. Prostate cancer trends in Canada: rising incidence or increased detection? Can Med Assoc J 1993;149:617-23.
20. Ries LAG, Kosary CL, Hankey BF, et al., eds. SEER cancer statistics review, 1973-94, Bethesda, MD: National Cancer Institute, 1997. (NIH publication no. 97-2789).
21. Potosky AL, Riley GF, Lubitz JD, et al. Potential for cancer related health services research using a linked MEDICARE-tumor registry database. Med Care 1993;31:732-48.
22. National Center for Health Statistics. International classification of diseases, Ninth Revision. Clinical Modification. 3rd ed. Vol. 1. Hyattsville MD: National Center for Health Statistics, 1989. (DHHS publication no. (PHS) 89-1260).
23. Physicians' Current Procedural Terminology. 4th ed. Department of Coding and Nomenclature. Chicago, IL: American Medical Association, 1991.
24. Simmons WR. Development of the design of the NCHS Hospital Discharge Survey. Hyattsville, MD: National Center for Health Statistics, 1970. (Vital and Health Statistics Series 2-39) Washington, DC: US GPO. (DHHS publication no. (PHS) 1000-).
25. Newman AJ Jr, Graham MA, Carlton CE Jr, et al. Incidental carcinoma of the prostate at the time of transurethral resection: importance of evaluating every chip. J Urol 1982;128: 948-50.
26. Sheldon CA, Williams RD, Fraley EE. Incidental carcinoma of the prostate: a review of the literature and critical reappraisal of classification. J Urol 1980;124:626-31.
27. Rohr LR. Incidental adenocarcinoma in transurethral resections of the prostate. Partial versus complete microscopic examination. Am J Surg Pathol 1987;11:53-8.
28. Bishop YMM, Fienberg SE, Holland PW. Discrete multivariate analysis. Cambridge, MA: MIT Press, 1975.
29. Kleinbaum DG, Kupper LL, Muller KE. Applied regression analysis of other multivariable methods. North Scituate, MA: Duxbury Press, 1988:266-8.
30. Chisholm GD, ed. Handbook on benign prostatic hyperplasia. Whitehouse Station, NJ: Merk & Co., Inc., 1994.
31. Kramer BS, Brown ML, Prorok PC, et al. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993;119:914-23.
32. Henkel J. Prostate cancer: new tests create treatment dilemmas. FDA Consumer, 1997. (Publication no. (FDA) 97-1220).
33. Johenning PW. A history of aspiration biopsy with special attention to prostate biopsy. Diagn Cytopathol 1988;4:265-8.
34. Koss LG. Aspiration biopsy - a tool in surgical pathology. Am J Surg Pathol 1988;12:43-53.
35. Walsh PC. Fine needle aspiration of the prostate - Why has it taken so long to accept? J Urol 1996;135:334-5.
36. Casey JH, Silenieks AI. Fine-needle aspiration cytology of the prostate: experience in a nonacademic practice. Semin Diagn Pathol 1988;5:294-300.
37. Drago JR. The role of new modalities in the early detection and diagnosis of prostate cancer. CA Cancer J Clin 1989;39:326-36.
38. Benson MC. Fine-needle aspiration of the prostate. Natl Cancer Inst Monogr 1988;7:19-24.
39. Bissada NK. Accuracy of transurethral resection of the prostate versus transrectal needle biopsy in the diagnosis of prostatic carcinoma. J Urol 1977;118:61.
40. Oesterling JE, Fuks Z, Lee CT, et al. Cancer of the prostate. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer principles and practice of oncology. 5th ed. Vol. 1. Philadelphia, PA: Lippincott-Raven, 1997:1323.
41. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327:1185-91.
42. Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993;22:291-9.
43. Prostate enlargement: benign prostatic hyperplasia. Bethesda, MD, National Institutes of Health, 1996. (NIH publication no. 91-3012).
44. SEER*Stat for Windows 95/NT Version 1.1. SEER cancer incidence public-use database, 1973-1995. Silver Spring, MD: Information Management Services, Inc., 1998.
45. Brown RS, Bergeron JW, Clement DG, et al. The Medicare risk program for HMOs - final summary report on findings from the evaluation. Final report under HCFA contract number 500-8-0006. Princeton, NJ: Mathematica Policy Research, Inc., 1993.
46. Riley G, Tudor C, Chiang YP, et al. Health status of Medicare enrollees in HMOs and fee-for-service in 1994. Health Care Finance Rev 1996;17:65-76.
47. Greenwald HP, Henke CJ. HMO membership, treatment, and mortality risk among prostatic cancer patients. Am J Public Health 1992;82:1099-104.